Nabilone, sold under the brand name Cesamet among others, is a synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain.

Numerous trials and case studies have demonstrated modest effectiveness for relieving fibromyalgia[4] and multiple sclerosis.

[4] A 2011 systematic review of cannabinoids for chronic pain determined there was evidence of safety and modest efficacy for some conditions.

[9] A study comparing nabilone with metoclopramide, conducted before the development of modern 5-HT3 antagonist anti-emetics such as ondansetron, revealed that patients taking cisplatin chemotherapy preferred metoclopramide, while patients taking carboplatin preferred nabilone to control nausea and vomiting.

[4] Adverse effects of nabilone include, but are not limited to: dizziness/vertigo, euphoria, drowsiness, dry mouth, ataxia, sleep disturbance, headache, nausea, disorientation, depersonalization, hallucinations, and asthenia.

[18] In 2007, Valeant acquired the United Kingdom and European Union rights to market nabilone from Cambridge Laboratories.